Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  American Journal of Gastroenterology

• Publication date

  1995-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 7872274
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis.

  2009cited by this paper
• Sulfasalazine Revisited

  1993cited by this paper
• Sulfasalazine and 5-ASA compounds.

  1992cited by this paper
• Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis.

  1992cited by this paper
• Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.

  1992cited by this paper
• Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.

  1992cited by this paper
• Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.

  1992cited by this paper
• Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.

  1992cited by this paper
• Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?

  1992cited by this paper
• Medical treatment of inflammatory bowel disease.

  1992cited by this paper
• Review article: new developments in the use of 5‐aminosalicylic acid in patients with inflammatory bowel disease

  1991cited by this paper
• Sulphasalazine in ulcerative colitis: in memoriam?

  1991cited by this paper
• Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.

  1991cited by this paper
• Lung and skin hypersensitivity to 5-aminosalicylic acid.

  1991cited by this paper
• Acute pancreatitis during oral 5-aminosalicylic acid therapy

  1990cited by this paper
• Topical treatment of ulcerative colitis.

  1990cited by this paper
• Mechanism of action of 5-aminosalicylic acid and its derivatives.

  1990cited by this paper
• Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.

  1990cited by this paper
• Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

  1989cited by this paper
• [Acute interstitial nephritis caused by 5-aminosalicylic acid?].

  1989cited by this paper
• Comparative efficacy of coated, oral 5‐aminosalicylic acid (Claversal * ) and sulphasalazine for maintaining remission of ulcerative colitis

  1989cited by this paper
• Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.

  1989cited by this paper
• Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.

  1989cited by this paper
• Food and Drug Administration's Gastrointestinal Drugs Advisory Committee. September 15-16, 1988. The ACG Committee on FDA-related matters. American College of Gastroenterology.

  1989cited by this paper
• Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.

  1988cited by this paper
• Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action?

  1988cited by this paper
• Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation.

  1988cited by this paper
• Hypersensitivity to 5-aminosalicylic acid in patients with ulcerative colitis.

  1987cited by this paper
• Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.

  1987cited by this paper
• Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.

  1987cited by this paper
• Influence of olsalazine on gastrointestinal transit in ulcerative colitis.

  1987cited by this paper
• Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.

  1986cited by this paper
• Olsalazine in active ulcerative colitis.

  1985cited by this paper
• Sulphasalazine and derivatives, natural killer activity and ulcerative colitis.

  1985cited by this paper
• Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.

  1984cited by this paper
• A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)

  1973cited by this paper
• Controlled trial of sulphasalazine in the treatment of ulcerative colitis

  1964cited by this paper
• Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

  1962cited by this paper

• Marked mucosal lipid shifts in treatment refractory inflammatory bowel disease: a lipidomic study

  2025cites this paper
• Harnessing the Human Microbiome for Innovative Drug Delivery Systems: Exploring Pharmacomicrobiomics and Targeted Therapies.

  2025cites this paper
• Colon-Targeted Poly(ADP-ribose) Polymerase Inhibitors Synergize Therapeutic Effects of Mesalazine Against Rat Colitis Induced by 2,4-Dinitrobenzenesulfonic Acid

  2024cites this paper
• N-Salicyloyl acidic amino acids are a promising colon-specific promoiety of riluzole against rat colitis

  2024cites this paper
• Drug-microbiota interactions: an emerging priority for precision medicine

  2023cites this paper
• Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease

  2022cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2020cites this paper
• AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

  2019cites this paper
• Ulcerative Proctitis and Anorectal Crohn’s Disease

  2018cites this paper
• American Gastroenterological Association Institute Guideline on the Management of Mild-Moderate Ulcerative Colitis

  2018cites this paper
• Repeated intensified infliximab induction – results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm

  2017cites this paper
• Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cites this paper
• Contrast and Comparison of Mesalamine Derivatives in the Treatment of Ulcerative Colitis

  2014cites this paper
• Drug Therapies for Ulcerative Proctitis: Systematic Review and Meta-analysis

  2014cites this paper
• Treatment of Ulcerative colitis in the elderly: A systematic Review

  2013cites this paper
• The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology.

  2013cites this paper
• How Important is Onset of Action in Ulcerative Colitis Therapy?

  2012cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2012cites this paper
• Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.

  2010cites this paper
• A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis

  2009cites this paper
• Clinical Medicine Insights: Geriatrics

  2008cites this paper
• European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

  2008cites this paper
• European evidence-based Consensus on the management of ulcerative colitis: Current management.

  2008cites this paper
• Duration of treatment with 5-aminosalicylic acid compounds.

  2007cites this paper
• Optimizing management of distal ulcerative colitis

  2006cites this paper
• Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.

  2006cites this paper
• Neuro-ophthalmologic manifestations of systemic disease: rheumatologic/Inflammatory.

  2004cites this paper
• [Induction and maintenance of remission in ulcerative colitis].

  2004influential citation
• Short‐term adverse effects of 5‐aminosalicylic acid agents in the treatment of ulcerative colitis

  2004cites this paper
• Traitement préventif de la rechute au cours de la rectocolite ulcéro-hémorragique

  2004influential citation
• Aminosalicylate Treatment in IBD continued ability to inhibit the activation of nuclear factor

  2004cites this paper
• Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

  2004cites this paper
• 30 Medical management of ulcerative colitis

  2003cites this paper
• Inflammatory bowel disease and the eye.

  2003cites this paper
• Medical management of ulcerative colitis

  2003cites this paper
• Medical therapy of inflammatory bowel disease for the 21st century.

  2003cites this paper
• Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis

  2002cites this paper
• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2002cites this paper
• Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis.

  2002cites this paper
• Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

  2002cites this paper
• REVIEW: Role of 5-Aminosalicylic Acid (5-ASA) in Treatment of Inflammatory Bowel Disease: A Systemic Review

  2002cites this paper
• Update in medical therapy of ulcerative colitis: a practical approach.

  2002cites this paper
• Increased Rectal Wall Thickness May Predict Relapse in Ulcerative Colitis: A Pilot Follow-Up Study by Ultrasonographic Colonoscopy

  2002cites this paper
• Pharmacotherapeutic options in inflammatory bowel disease: an update.

  2001cites this paper
• Pharmacotherapeutical options in inflammatory bowel disease: an update

  2001cites this paper
• Remission maintenance in ulcerative colitis

  2000cites this paper
• Trends in Inflammatory Bowel Disease Therapy 1999

  2000cites this paper
• Drug-Induced Diarrhoea

  2000cites this paper
• Sulphasalazine, olsalazine and sulphapyridine induce mitogenic actions in the rat intestinal epithelium

  1997cites this paper
• Alternatives to Sulfasalazine: A Meta‐analysis of 5‐ASA in the Treatment of Ulcerative Colitis

  1997cites this paper
• Escherichia Coli and Ulcerative Colitis

  1997cites this paper
• Medical treatment for inflammatory bowel disease – refinements and new modalities

  1997cites this paper
• Optimizing therapy for inflammatory bowel disease.

  1997cites this paper
• Ulcerative Colitis

  1954cites this paper